Komori
StemRIM (4599) · InitiativeAchieved

Capital reduction to preserve flexibility and agility in capital policy

First written in FY2021-Q1. 8 of 14 entries say "Advanced", first in FY2022-Q1. Latest entry: FY2026.

14entries
7years
3from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2021-Q1 – FY2021-Q3AdvancedFY2022-Q1 – FY20262020: 12021: 320212022: 120222023: 220232024: 220242025: 120252026: 42026
Same theme, other companies

39 other companies' latest entry also says "Achieved".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 61 companies compared. The sentences above are computed from all 61.
Full recordFilings, disclosures and news, newest first
  1. FY2026AchievedAnnual report

    「The capital reduction that took effect on 30 July 2026 reduced share capital by ¥75.755 million and increased the capital reserve by ¥75.755 million.」

    A capital reduction designed to ensure flexibility and agility in capital policy took effect on 30 July 2026, completing the procedure to reduce share capital to ¥10 million.
  2. FY2025AchievedAnnual report

    「The capital reduction effective 30 July 2025 reduced stated capital by ¥106.4 million and increased the capital reserve by ¥106.4 million.」

    The capital reduction intended to secure flexibility and agility in capital policy took effect on 30 July 2025, completing the procedure to reduce stated capital to ¥10 million.
  3. FY2024AchievedAnnual report

    「The capital reduction effective 30 July 2024 reduced stated capital by ¥208.071 million and increased the capital reserve by ¥208.071 million.」

    The capital reduction plan intended to secure flexibility and agility in capital policy and reduce the tax burden took effect on 30 July 2024, completing the implementation.
  4. FY2024-Q3AdvancedAnnual report

    「To secure flexibility and agility in future capital policy and reduce the tax burden, the Company will reduce the amount of stated capital and transfer the reduction to the capital reserve pursuant to Article 447, Paragraph 1 of the Companies Act. Of the ¥218,071,950 in stated capital as of 8 May 2024, ¥208,071,950 will be reduced, leaving ¥10,000,000. The effective date of the capital reduction is scheduled for 30 July 2024.」

    A capital reduction plan was approved to reduce stated capital by ¥208,071,950 from ¥218,071,950 to ¥10,000,000, with the aim of securing flexibility and agility in capital policy and reducing the tax burden. The scheduled effective date is 30 July 2024.
  5. FY2023AdvancedAnnual report

    「Based on a resolution of the Extraordinary General Meeting of Shareholders held on 26 July 2023, the capital reduction took effect on 29 July 2023. Stated capital was reduced and the reduction was transferred to the capital reserve. As a result, stated capital decreased by ¥198.573 million, or 92.7%, and the capital reserve increased by ¥198.573 million.」

    The capital reduction plan disclosed previously progressed, and on 29 July 2023, stated capital was reduced by ¥198.573 million and an equal amount was transferred to the capital reserve.
  6. FY2023-Q3AdvancedAnnual report

    「At a meeting of the Board of Directors held on 17 May 2023, the Company resolved to set a record date for convening an Extraordinary General Meeting of Shareholders scheduled for 26 July 2023, to hold the meeting, and to submit the proposal entitled “Reduction in the Amount of Stated Capital (Capital Reduction).”」

    A capital reduction plan was approved to reduce stated capital by ¥149,571,400 from ¥159,571,400 to ¥10,000,000, with the aim of securing flexibility and agility in capital policy and reducing the tax burden. The implementation procedures were further specified.
  7. FY2023-Q1AdvancedAnnual report

    「At a meeting of the Board of Directors held on 22 September 2022, the Company resolved to submit to the 17th Annual General Meeting of Shareholders, held on 26 October 2022, proposals for reducing the amounts of capital and the capital reserve and disposing of surplus as set out below. The proposals were approved at the annual general meeting and took effect on 1 December 2022.」

    A capital policy reducing stated capital of ¥118,960,500 and the capital reserve of ¥2,064,033,607 was approved and took effect on 1 December 2022. An additional capital reduction was implemented to secure flexibility and agility in capital policy.
  8. FY2022-Q1AdvancedAnnual report

    「At a meeting of the Board of Directors held on 22 September 2021, the Company resolved to submit the following proposal for a reduction in the amount of stated capital to the 16th Annual General Meeting of Shareholders held on 27 October 2021. The proposal was approved at the meeting, and the reduction took effect on 1 December 2021.」

    A capital reduction intended to secure flexibility and agility in capital policy was implemented, reducing stated capital by ¥37,936,750 from ¥47,936,750 to ¥10,000,000. The procedure was completed.
  9. FY2021-Q3RestatedAnnual report

    「Based on a resolution of the Annual General Meeting of Shareholders held on 28 October 2020, the capital reduction took effect on 1 December 2020. Stated capital was reduced and the reduction was transferred to the capital reserve. As a result, stated capital decreased by ¥73.013 million, or 81.2%, and the capital reserve increased by ¥73.013 million.」

    It has been reaffirmed that the capital reduction intended to secure flexibility and agility in capital policy took effect on 1 December 2020.
  10. FY2021-Q2RestatedAnnual report

    「Based on a resolution of the Annual General Meeting of Shareholders held on 28 October 2020, the capital reduction took effect on 1 December 2020. Stated capital was reduced and the reduction was transferred to the capital reserve. As a result, stated capital decreased by ¥73.013 million, or 81.2%, and the capital reserve increased by ¥73.013 million.」

    The capital reduction intended to secure flexibility and agility in capital policy took effect on 1 December 2020, and ¥73.013 million of stated capital was transferred to the capital reserve.
  11. FY2021-Q1First statedAnnual report

    「At a meeting of the Board of Directors held on 24 September 2020, the Company resolved to submit a proposal to reduce the amount of stated capital to the 15th Annual General Meeting of Shareholders held on 28 October 2020. The proposal was approved at the meeting, and the reduction took effect on 1 December 2020. To secure flexibility and agility in future capital policy, the Company reduced the amount of stated capital and transferred the reduction to the capital reserve pursuant to Article 447, Paragraph 1 of the Companies Act.」

    A capital reduction was resolved and implemented, reducing stated capital by ¥73,013,000 from ¥83,013,000 to ¥10,000,000 and transferring the reduction to the capital reserve. Unlike the previous elimination of accumulated losses, this measure was intended to secure flexibility and agility in capital policy.
Moved together

"Clinical development of HMGB1 peptides for multiple indications" moved the same way as this thread, in the same document, in 7 of its 14 moves.

766654★123456
  1. ★This thread
  2. 1Clinical development of HMGB1 peptides for multiple indications7×
  3. 2Initiating clinical trials for osteoarthritis of the knee, cardiomyopathy and cirrhosis6×
  4. 3Strengthening the financial base through funding from capital markets and investors6×
  5. 4Fixed compensation and stock options to promote long-term corporate value creation6×
  6. 5Increasing incentives to contribute to R&D and auditing through stock options5×
  7. 6Applying for approval of an epidermolysis bullosa treatment following the Phase II trial4×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for StemRIM yet. It last moved in the General Meetings of Shareholders of 2026-07-04: "Advanced".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.